NCT02872766View on ClinicalTrials.gov

Evaluation of the Safety and Efficacy of Corneal Cross Linking for the Treatment of Myopia.

NATerminatedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

January 31, 2018

Study Completion Date

January 31, 2018

Conditions
Myopia
Interventions
DEVICE

CXL Myopia

Applying riboflavin 0,22% to 0,25 % up to 20 minutes . Then, the eyes are exposed to UVA light with the KXL II system according to the programmed treatment pattern.

Trial Locations (1)

Unknown

Toulouse University Hospital, Toulouse

Sponsors

Collaborators (1)

Glaukos Corporation
All Listed Sponsors
collaborator

Glaukos Corporation

INDUSTRY

lead

University Hospital, Toulouse

OTHER